297 related articles for article (PubMed ID: 32680650)
1. Targeting EMT in Cancer with Repurposed Metabolic Inhibitors.
Ramesh V; Brabletz T; Ceppi P
Trends Cancer; 2020 Nov; 6(11):942-950. PubMed ID: 32680650
[TBL] [Abstract][Full Text] [Related]
2. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
4. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
5. Targeting CTGF in Cancer: An Emerging Therapeutic Opportunity.
Shen YW; Zhou YD; Chen HZ; Luan X; Zhang WD
Trends Cancer; 2021 Jun; 7(6):511-524. PubMed ID: 33358571
[TBL] [Abstract][Full Text] [Related]
6. Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal transition via up-regulation of Snail in MCF7 human breast cancer cells.
Zhang W; Feng M; Zheng G; Chen Y; Wang X; Pen B; Yin J; Yu Y; He Z
Biochem Biophys Res Commun; 2012 Jan; 417(2):679-85. PubMed ID: 22166209
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?
van Staalduinen J; Baker D; Ten Dijke P; van Dam H
Oncogene; 2018 Nov; 37(48):6195-6211. PubMed ID: 30002444
[TBL] [Abstract][Full Text] [Related]
8. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer.
Toden S; Okugawa Y; Jascur T; Wodarz D; Komarova NL; Buhrmann C; Shakibaei M; Boland CR; Goel A
Carcinogenesis; 2015 Mar; 36(3):355-67. PubMed ID: 25653233
[TBL] [Abstract][Full Text] [Related]
9. A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.
Mak MP; Tong P; Diao L; Cardnell RJ; Gibbons DL; William WN; Skoulidis F; Parra ER; Rodriguez-Canales J; Wistuba II; Heymach JV; Weinstein JN; Coombes KR; Wang J; Byers LA
Clin Cancer Res; 2016 Feb; 22(3):609-20. PubMed ID: 26420858
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated macrophages and epithelial-mesenchymal transition in cancer: Nanotechnology comes into view.
Vakili-Ghartavol R; Mombeiny R; Salmaninejad A; Sorkhabadi SMR; Faridi-Majidi R; Jaafari MR; Mirzaei H
J Cell Physiol; 2018 Dec; 233(12):9223-9236. PubMed ID: 30078227
[TBL] [Abstract][Full Text] [Related]
11. Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations.
Kumar N; Cramer GM; Dahaj SAZ; Sundaram B; Celli JP; Kulkarni RV
Sci Rep; 2019 Jul; 9(1):10845. PubMed ID: 31350465
[TBL] [Abstract][Full Text] [Related]
12. Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance.
Dudas J; Ladanyi A; Ingruber J; Steinbichler TB; Riechelmann H
Cells; 2020 Feb; 9(2):. PubMed ID: 32059478
[TBL] [Abstract][Full Text] [Related]
13. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
14. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical E-cadherin increase in 5FU-resistant colon cancer is unaffected during mesenchymal-epithelial reversion induced by γ-secretase inhibition.
Dinicola S; Pasqualato A; Proietti S; Masiello MG; Palombo A; Coluccia P; Canipari R; Catizone A; Ricci G; Harrath AH; Alwasel SH; Cucina A; Bizzarri M
Life Sci; 2016 Jan; 145():174-83. PubMed ID: 26746659
[TBL] [Abstract][Full Text] [Related]
16. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis.
Jung HY; Fattet L; Yang J
Clin Cancer Res; 2015 Mar; 21(5):962-968. PubMed ID: 25107915
[TBL] [Abstract][Full Text] [Related]
17. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells.
Fortunato A
Cell Oncol (Dordr); 2017 Aug; 40(4):367-378. PubMed ID: 28593575
[TBL] [Abstract][Full Text] [Related]
18. Emerging role of tumor microenvironment derived exosomes in therapeutic resistance and metastasis through epithelial-to-mesenchymal transition.
Balaji S; Kim U; Muthukkaruppan V; Vanniarajan A
Life Sci; 2021 Sep; 280():119750. PubMed ID: 34171378
[TBL] [Abstract][Full Text] [Related]
19. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
20. Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.
Zahan T; Das PK; Akter SF; Habib R; Rahman MH; Karim MR; Islam F
Anticancer Agents Med Chem; 2020; 20(18):2190-2206. PubMed ID: 32748758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
